Vanguard Group Inc. grew its stake in Exactech, Inc. (NASDAQ:EXAC) by 1.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 415,253 shares of the medical equipment provider’s stock after purchasing an additional 6,594 shares during the quarter. Vanguard Group Inc. owned about 2.90% of Exactech worth $12,375,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Bank of Montreal Can bought a new position in Exactech in the 2nd quarter worth $134,000. Russell Investments Group Ltd. raised its holdings in Exactech by 13.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 47,118 shares of the medical equipment provider’s stock worth $1,405,000 after purchasing an additional 5,485 shares in the last quarter. Prudential Financial Inc. bought a new position in Exactech in the 2nd quarter worth $359,000. Schwab Charles Investment Management Inc. raised its holdings in Exactech by 30.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 70,248 shares of the medical equipment provider’s stock worth $2,094,000 after purchasing an additional 16,330 shares in the last quarter. Finally, AJO LP bought a new position in Exactech in the 2nd quarter worth $483,000. Institutional investors and hedge funds own 64.58% of the company’s stock.
Shares of Exactech, Inc. (NASDAQ:EXAC) opened at $41.80 on Tuesday. The firm has a market cap of $600.51, a PE ratio of 34.54, a PEG ratio of 3.59 and a beta of 1.04. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.08 and a quick ratio of 2.09. Exactech, Inc. has a 1 year low of $23.30 and a 1 year high of $42.75.
Several research analysts have commented on EXAC shares. BidaskClub lowered shares of Exactech from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Gabelli restated a “buy” rating on shares of Exactech in a report on Monday, July 31st. Robert W. Baird set a $34.00 target price on shares of Exactech and gave the stock a “buy” rating in a research report on Sunday, October 15th. Sidoti downgraded shares of Exactech from a “buy” rating to a “neutral” rating in a research report on Monday, October 23rd. Finally, Zacks Investment Research downgraded shares of Exactech from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. One research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $42.00.
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Want to see what other hedge funds are holding EXAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exactech, Inc. (NASDAQ:EXAC).
Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.